Novo Nordisk's New Weight-Loss Pill Shows Promising Results
Novo Nordisk's new amylin-based obesity drug, amycretin, shows significant weight loss in early trials, but similar efficacy across different doses and high side effects raise questions about optimal dosing strategies.